

Enantiopure C^{α} -tetrasubstituted α -amino acids. Chemoenzymatic synthesis and application to turn-forming peptides

Bernard Kaptein,^a Quirinus B. Broxterman,^a Hans E. Schoemaker,^a Floris P. J. T. Rutjes,^b Johan J. N. Veerman,^c Johan Kamphuis,^d Cristina Peggion,^e Fernando Formaggio^e and Claudio Toniolo^{e,*}

^aDSM Research, Organic Chemistry and Biotechnology Section, P.O. Box 18, 6160 MD Geleen, The Netherlands

^bDepartment of Organic Chemistry, University of Nijmegen, 6525 ED Nijmegen, The Netherlands

^cInstitute of Molecular Chemistry, University of Amsterdam, 1018 WS Amsterdam, The Netherlands

^dDSM Food Specialties, Nutritional Ingredients, P.O. Box 1, 2600 MA Delft, The Netherlands

^eDepartment of Organic Chemistry, Biopolymer Research Centre, C.N.R., University of Padova, Via Marzolo 1, 35131 Padova, Italy

Received 2 January 2001; revised 15 February 2001; accepted 23 February 2001

Abstract—By a chemo-enzymatic approach we carried out a large-scale synthesis of four enantiopure, sterically constrained, C^{α} -tetrasubstituted α -amino acids, all characterized by a sidechain $C^{\gamma}C^{\delta}$ double bond. By using one of them (L-Mag), we prepared an N^{α} -protected tetrapeptide benzylamide which was shown to adopt a β-turn conformation and to efficiently undergo ring-closing olefin metathesis. © 2001 Elsevier Science Ltd. All rights reserved.

1. Introduction

Chiral C^{α} -tetrasubstituted α -amino acids are increasingly attracting attention as useful building blocks for the production of naturally occurring and tailor-made derivatives of pharmaceutical and agricultural interest. ¹⁻⁴ In addition, it has been unambiguously demonstrated that these synthons, in analogy with their achiral prototype α -aminoisobutyric acid (Aib) (1),⁵⁻¹⁰ are able to dramatically reduce the conformational freedom of the peptides in which they are incorporated. Indeed, detailed experimental investigations ¹¹⁻¹³ have shown that peptides rich in chiral C^{α} -tetrasubstituted α -amino acids either fold in screw-sense biased β -turns ¹⁴⁻¹⁶ and 3_{10} -helical structures ¹⁷ or adopt planar, fully-extended (C_5) conformations. ^{15,18,19} The stabilization of specific ordered secondary structures has recently become a major issue in peptide science, with special emphasis to the design of rigidified catalysts, spacers, and templates (for leading review articles see Refs. 20–22).

In this context, allyl-type, chiral C^{α} -tetrasubstituted α -amino acids are of emerging relevance for the additional potential ability of their peptides to undergo a wide range of transformations at the C^{γ} — C^{δ} bond, including Grubbs' intramolecular, side-chain to side-chain, ring-closing olefin metathesis. ^{23,24} The preparation of 'built-into' com-

pounds $^{25-35}$ and cyclic peptides via intramolecular carbon–carbon formation $^{36-43}$ has been already reported for allyl-based, chiral C^{α} -trisubstituted α -amino acids and peptides. For the first time, Verdine and coworkers 44 have recently extended the exploding field of ring-closing metathesis to peptides characterized by C^{α} -methyl-L-allyl-glycine (L-Mag) (L-2a) and related residues.

Keywords: amino acids and derivatives; metathesis; NMR; peptides and polypeptides.

Corresponding author. Tel.: +39-49-8275247; fax: +39-49-8275239; e-mail: biop02@chor.unipd.it

 $R = -CH_2 - CH = CH_2 \cdot (a); -CH_2 - C(CH_3) = CH_2 \cdot (b); -CH_2 - CH = C(CH_3)_2 \cdot (c); -CH_2 - CH = CH - \Phi \cdot (d)$

Scheme 1.

As part of a programme dealing with chemistry and structural characterization of allyl-type, C^{α} -tetrasubstituted α -amino acids, and their derivatives and peptides, ^{25,44-63} in this article we describe the large-scale synthesis of the four enantiopure α -amino acids L-2a-d. We also prepared and investigated the preferred conformation of: (i) a linear, N^{α}-protected tetrapeptide benzylamide containing one residue of L-Mag (L-2a) and one of its unmethylated counterpart L-allylglycine (L-Agl) (L-3), and (ii) its sidechain to side-chain, ring-closing olefin metathesis/hydrogenation derivative.

2. Results and discussion

2.1. Amino acid synthesis and enzymatic resolution

A variety of methods for the synthesis of enantiomerically pure C^{α} -tetrasubstituted α -amino acids (recently reviewed in Ref. 64) have been described. At DSM Research we concentrated on the preparation of this type of amino acids via enzymatic resolution of racemic α -amino amides. This route is especially attractive for large-scale preparation since the racemic α -amino amide substrates are readily accessible and the enzymatic resolution can be easily scaled-up and proceeds with high stereoselectivity. Currently, we have three amidases available for α -amino amide resolution. ⁶⁵ The L-aminopeptidase from *Pseudomonas putida* ATCC 12633 is used for the enzymatic resolution of C^{α} -trisubstituted α -amino amides. This enzyme has recently

been cloned and overexpressed in an E. coli K-12 host microorganism. For the resolution of C^{α} -tetrasubstituted α -amino amides two amidases (from Mycobacterium neoaurum ATCC 25795 and Ochrobactrum anthropi NCIMB 40321, respectively) are available, both exhibiting a high L-stereoselectivity. The amidase from the latter species is also able to stereoselectively hydrolyze C^{α} -trisubstituted α -amino amides.

Racemic C^{α} -tetrasubstituted α -amino amides (7b-d) were prepared by PTC (phase-transfer catalyzed) alkylation of N-benzylidene-D,L-alaninamide 4 (Scheme 1), as previously described for 7a. 46 With allyl-type bromides 5a, c and d C^{α} -alkylation is fast and proceeds to high conversion. After acidic work-up of the racemic Schiff bases 6a, c and **d**, the racemic C^{α} -tetrasubstituted α -amino amides **7a**, **c** and **d** were all obtained in 72-73% yield. In the alkylation reactions with prenyl (3,3-dimethallyl) bromide (5c) or cinnamyl bromide (5d) a complete S_N2 reaction occurred and no $S_N 2'$ product was observed. C^{α} -Alkylation of 4 with 3-bromo-2-methyl-1-propene **5b** (or 3-chloro-2-methyl-1propene) proceeded only to low conversion. In addition, a substantial amount of byproducts occurred, which made the purification of the reaction mixture difficult. All attempts to improve the yield of this reaction failed.

The four racemic substrates 7a-d were subjected to enzymatic hydrolysis using the amidases from M. $neoaurum^{48,66}$ and O. $anthropi^{67}$ (Scheme 2). Thus, the stereoselectivity of the two enzymes could be compared. In general, the

$$H_3C$$
 R H_2N H_2 H_2N H_2 H_3C R H_2N H_2 H_2N H_2 H_3C R H_2N H_2 H_3C R H_2N H_2 H_3C R H_2 H_3 H_3 H_3 H_4 H_5 H_5

Table 1. Results of the enzymatic resolutions

Substrate	R	Amidase	Conversion (%)	e.e. _{amide} (%)	e.e. _{acid} (%)	E-ratio
7a	−CH ₂ −CH=CH ₂	M. neoaurum	40	63	92	46
		O. anthropi	64	50	27	2.7
7b	$-CH_2-C(CH_3)=-CH_2$	M. neoaurum	46	85	98	>250
	2 , 3, 2	O. anthropi	46	72	85	27
7c	$-CH_2-CH=-C(CH_3)_2$	M. neoaurum	45	80	98	>250
	2 (3/2	O. anthropi	62	98	61	17
7d	-CH₂-CH=CH-Ph	M. neoaurum	51	≥98	95	≥180
	-	O. anthropi	31	45	96	79 ^a

^a At 40–50% conversion the *E*-ratio is 65–69.

enzymatic resolutions are performed on a 10% aqueous solution of the substrate. With the M. neoaurum amidase the initial pH was set at 8.0–8.5. With the amidase from O. anthropi a starting pH between 6 and 8 was applied as this enzyme has a much broader pH optimum. Since the enzyme reactions are not buffered, the pH during the reaction increased to 9.6 due to the formation of ammonia. The conversion of the resolution reactions was measured using an ammonia sensitive electrode. After the appropriate reaction time, in general between 6 and 24 h, the crude cell mass was removed by centrifugation and the amide and acid were separated by ion-exchange chromatography (strongly basic resin). The results of these enzymatic resolutions are listed in Table 1. If necessary, the e.e. values of the L-acids can be improved by recrystallization from isopropanol/ water.

In all resolution experiments the L-enantiomer of the amide was preferably hydrolysed to the L-amino acid, L-2a-d, leaving the D-enantiomer of the amide, D-7a-d, behind. The observed stereoselectivity is clearly a result of steric interactions during the enzyme reaction. For the M. neoaurum amidase an active site model was suggested in which a small hydrophobic pocket is present and able

to contain the C^{α} -methyl substituent of the amides 7a-d. 48,62,66 Larger substituents, like an ethyl or an allyl group, are accepted with great difficulty, which results in a slow hydrolysis of the D-enantiomer. In general, the enantiomeric ratio E^{68} improves with increasing size of the large substituent. As already known from earlier results, 48,66 branching at the α -amino amide β -position results in a complete stereoselectivity (E > 250) for the amidase from M. neoaurum, as well as for that from O. anthropi. From the current results it can be concluded that increasing the branching at the γ -(7b) and to a somewhat lesser extent also at the δ -position (7c and 7d) has a similar effect.

Hydrogenation of the double bond of C^{α} -methyl-D,L-allylglycinamide (7a) substantially improves the stereoselectivity of both enzymes. Indeed, C^{α} -methyl-D,L-norvalinamide is hydrolysed by M. neoaurum amidase with a nearly complete stereoselectivity (E>232), while the enantiomeric ratio with the amidase from O. anthropi is enhanced from 27 to 97.⁶⁹ Similarly, C^{α} -methyl-D,L-leucinamide, the hydrogenated analogue of 7b, is hydrolysed with full stereoselectivity by the amidase from both species. 48,65,66,70

Figure 1. Representation of Grubbs' alkene-stabilized -L-Pro-Aib- β-turn peptide 8, our linear β-turn peptide Boc-L-Agl-L-Pro-Aib-L-Mag-NHBzl 9, Balaram's disulfide-stabilized -L-Pro-Aib- β-turn peptide 10, and our alkane-stabilized -L-Pro-Aib- β-turn peptide 17.

17

Scheme 3.

On the other hand, replacing of the C^{α} -methyl group of **7a** by a phenyl group (i.e. C^{α} -phenyl-D,L-allylglycinamide) results in the complete loss of activity of the *M. neoaurum* amidase, whereas the *S*-enantiomer is still hydrolysed by the *O. anthropi* amidase (E>200).

In summary, the active site of the *O. anthropi* amidase can bind larger substrates than those of the amidase from *M. neoaurum*. Therefore, the more open active site of *O. anthropi* results in a lower stereoselectivity for the substrates **7a**–**d** as compared to *M. neoaurum*.

2.2. Peptide synthesis, metathesis and conformational characterization


In this work we exploited the simplest of the four allyl-type, C^{α} -tetrasubstituted α -amino acids discussed above, i.e. L-Mag (L-2a), in the C=C covalent stabilization of a tetrapeptide \(\beta\)-turn conformation involving a ring-closing metathesis/hydrogenation approach. To this aim we decided to partly modify the terminally blocked -L-Agl-L-Pro-Aib-L-Agl- sequence, shown to undergo olefin ring-closing metathesis to 8 (Fig. 1) in 60% yield by Grubbs and coworkers, ³⁶ by replacing the L-Agl (L-3) residue in position 4 with its C^{α} -methylated counterpart L-Mag (L-2a). The reasons for our choice of the -L-Agl-L-Pro-Aib-L-Magsequence 9 were based on the following observations: (i) The -L-Pro-Aib- dipeptide is expected to easily fold into a β -turn conformation. ^{36,72,73} (ii) L-Mag (L-2a) is known to overwhelmingly prefer φ,ψ backbone torsion angles in the right-handed helical region of the conformational space. 62,63 (iii) An X-ray diffraction analysis of 10, the disulfide analogue of 8, carried out by Balaram and coworkers, 72 clearly showed that, while Cys1 is semiextended, Cys⁴ is helical.

The Boc (tert-butoxycarbonyl) N^{α} -protected derivatives, including those of L-Agl (11)^{74,75} and L-Mag,⁶² were prepared in excellent yield by reacting the free amino acid with (Boc)₂O (di-tert-butyldicarbonate) in an aqueous/dioxane mixture. The Boc-L-Mag-NHBzl (NHBzl, benzylamino) (12) C-terminal derivative was synthesized by using *N*-ethyl,*N'*-[3-(dimethylamino)propyl]-carbodiimide (EDC) as the dehydrating agent. Synthesis of the linear tetrapeptide 9 was performed step-by-step in solution via the intermediates Boc-Aib-L-Mag-NHBzl (13) and Boc-L-Pro-Aib-L-Mag-NHBzl (14), beginning from the C-terminal H-L-Mag-NHBzl. Peptide bond formation was achieved by the EDC/HOAt (1-hydroxy-7-aza-1,2,3-benzotriazole) method⁷⁶ in CH₂Cl₂ in the presence of the tertiary amine *N*-methylmorpholine (NMM). Using this approach, the

three sterically hindered peptide bonds were obtained in satisfactory yields. Removal of the Boc N^{α} -protecting group was performed by treatment with diluted trifluoroacetic acid (TFA).

While stirring of the linear Agl/Mag tetrapeptide diene 9 in the presence of 5 mol% of the conventional, Ru-based Grubbs' catalyst⁷⁷ resulted in complete recovery of the starting material (even at high temperatures), subjection of 9 to the newly developed, very active, thermally stable, dihydroimidazolylidene catalyst analogue (15)⁷⁸ led, after 16 h at 80°C, to the ring-closed, olefin product 16 as a mixture of two C=C bond diastereomers in 82% isolated yield (Scheme 3). Unfortunately, the isomers were not separable by regular column chromatography nor by HPLC. Subsequent hydrogenation of the isomeric mixture 16 with H₂/PtO₂ in ethyl acetate resulted in a clean reduction of the C=C bond to the saturated carbon–carbon cyclic tetrapeptide 17 in 85% isolated yield.

To ascertain the type of conformation preferentially formed in solution by the cyclic compound 17 and its linear precursor 9 we performed a ¹H NMR investigation of the two tetrapeptides. The analysis was carried out in CDCl₃ at 1.0 mM concentration. All NH proton resonances were assigned by means of 2D ROESY experiments. The participation of specific NH groups in H-bonding was established by examining the behaviour of the NH resonances upon addition of perturbing agents. In particular, we investigated the solvent dependence of NH chemical shifts, by adding an increasing amount of the strong H-bonding acceptor solvent dimethylsulphoxide (DMSO)^{79,80} to the CDCl₃ solution, and the line broadening of NH resonances induced by adding the free radical TEMPO (2,2,6,6-tetramethylpiperidinyl-1-oxo).⁸¹ Fig. 2 shows the behaviour of the NH resonances of the linear tetrapeptide 9 upon addition of DMSO and TEMPO. In this peptide only the N(3)H proton chemical shift is sensitive to the addition of DMSO and its resonance broadens upon addition of the paramagnetic TEMPO. All the other protons display a behaviour characteristic of shielded protons, as their chemical shifts appear relatively insensitive to solvent composition and






Figure 2. 1 H NMR titrations of the linear tetrapeptide Boc-L-Agl-L-Pro-Aib-L-Mag-NHBzl 9. (A) Plot of NH chemical shifts as a function of increasing percentages of DMSO added to the CDCl₃ solution (v/v). (B) Plot of bandwidth of the NH signals as a function of increasing percentages of TEMPO (w/v) in CDCl₃ solution. Peptide concentration: 1.0 mM.


their linewidths are not influenced by addition of TEMPO. The cyclic tetrapeptide **17** behaves in a similar manner (Fig. 3)

From our 1H NMR study and the known conformational tendencies of the $Pro^{82,83}$ and Aib^{5-10} corner residues it is reasonable to conclude that the most populated conformation adopted in $CDCl_3$ solution by both terminally protected tetrapeptides $\boldsymbol{9}$ and $\boldsymbol{17}$ involves a β -turn centred at the -L-Pro^2-Aib^3- sequence with an intramolecular transannular H-bond connecting the N(4)H and C'1=O1 groups. The ROESY spectra of both peptides show a remarkably

intense cross-peak between the $C^{\alpha}(2)H$ and N(3)H protons (Fig. 4), the typical signature of a type-II β -turn conformation. ^{14–16} The overall preferred structure of both peptides must be quite compact, as the N(1)H and benzylamide NH protons as well appear to be highly solvent shielded.

3. Conclusions

By a chemo-enzymatic approach we have been able to synthesize in a large amount four enantiopure C^{α} -tetra-






Figure 3. ¹H NMR titrations of the cyclized/reduced tetrapeptide Boc-L-Agl*-L-Pro-Aib-L-Mag*-NHBzl **17** (starred residues refer to those with the side chain modified by cyclization). (A) Plot of NH chemical shifts as a function of increasing percentages of DMSO added to the CDCl₃ solution (v/v). (B) Plot of bandwidth of the NH signals as a function of increasing percentages of TEMPO (w/v) in CDCl₃ solution [the NH(Bzl) proton is under the benzyl aromatic protons]. Peptide concentration: 1.0 mM.




Figure 4. Partial ROESY spectra of (A) the linear tetrapeptide Boc-L-Agl-L-Pro-Aib-L-Mag-NHBzl 9 and (B) its cyclized/reduced derivative 17 in CDCl₃ solution.

substituted α -amino acids carrying a side chain of the allyl type. One of them, L-Mag (L-2a), was incorporated in a terminally blocked tetrapeptide (9), a model compound for ring-closing olefin metathesis. This reaction proceeds smoothly with a newly developed Grubbs' catalyst. Reduction of the cyclized olefin diastereomeric mixture 16 afforded 17, a peptide with a fully hydrogenated all-hydrocarbon cross-linking system.

The linear tetrapeptide diene precursor 9 and the final cyclic product 17 share a common conformational preference, in particular an intramolecularly H-bonded type-II β-turn motif. We conclude that preorganization in the linear precursor 9, characterized by two allyl-based residues separated by two turn-forming residues in the amino acid sequence, favours ring closure and generates peptide 17, in which the β-turn conformation is frozen by a side-chain to side-chain, 4-carbon cross-link. Compared to Grubbs' olefin cyclopeptide 8 and Balaram's disulfide analogue 10, our linear and cyclic peptides (9 and 17, respectively) appear to be more markedly intramolecularly H-bonded, and hence, presumably, more extensively folded. We attribute this structural propensity to the presence of the severely conformationally constrained, turn/helix forming, C^{α} -tetrasubstituted α-amino acid Mag in 9 and its metathesized side-chain derivative in 17.

4. Experimental

4.1. General

4.1.1. Amino acid and peptide synthesis. L-Allylglycine (2-amino-L-4-pentenoic acid) (L-3) is an ACROS product. Melting points were determined using a Leitz model Laborlux 12 apparatus and are not corrected. Optical rotations were measured using a Perkin–Elmer model 241 polarimeter equipped with a Haake model D thermostat. Thinlayer chromatography was performed on Merck Kieselgel

60/F₂₅₄ precoated plates. The solvent systems used are: (I) chloroform/ethanol (9:1); (II) 1-butanol/acetic acid/water (3:1:1); (III) toluene/ethanol (7:1); (IV) ethyl acetate (EtOAc). The chromatograms were developed by quenching of UV fluorescence, chlorine—starch—potassium iodide or ninhydrin chromatic reaction, as appropriate. Enantiomeric excesses (e.e.) were determined by HPLC after precolumn derivatization with *o*-phthaldehyde/(*R*)-3-mercaptoisobutyric acid according to Duchateau et al.⁸⁴ [eluent: 50 mM sodium acetate solution (titrated to pH 6.0 with acetic acid)/methanol 7:3]. Grubbs' catalyst 15 was prepared according to the literature procedure.⁷⁸ The synthesis and characterization of H-D,L-Mag-NH₂ (7a), H-L-Mag-OH (L-2a), and H-D-Mag-NH₂ (D-7a) have already been described.⁴⁶

4.1.2. C^{α} -Methyl-D,L-(γ-methyl)allylglycinamide (7b). This compound was prepared as described for H-D,L-Mag-NH₂ (7a), ⁴⁶ starting from *N*-benzylidene-D,L-alaninamide (4) (470 g, 2.7 mol) and 3-chloro-2-methyl-1-propene (285 mL, 2.9 mol). The *title compound*, obtained as a colourless oil after vacuum distillation (39 g, 10%), crystallized on standing, mp 70–72°C, bp 115–130°C (0.2 mmHg); $\delta_{\rm H}$ (200 MHz, CDCl₃) 7.48 and 6.00 (2H, 2 br s, amide N H_2), 4.82 and 4.66 (2H, 2m, allyl δC H_2), 2.80 and 1.99 (2H, 2 d, allyl βC H_2), 1.64 (3H, s, allyl δC H_3), 1.45 (2H, s, amine N H_2), 1.25 (3H, s, βC H_3); $\delta_{\rm C}$ (50 MHz, CDCl₃) 178.78 (s, CO), 141.71 (γC), 114.63 (t, δCH₂), 55.84 (s, αC), 48.28 (t, βCH₂), 28.41 (q, δCH₃), 22.79 (q, βCH₃); HRMS (FAB): MH⁺, found 143.1169. C₇H₁₅N₂O requires 143.1184.

4.1.3. C^{α} -Methyl-D,L-prenylglycinamide (7c). This compound was prepared as described for H-D,L-Mag-NH₂ (7a), ⁴⁶ starting from *N*-benzylidene-D,L-alaninamide (4) (17.2 g, 0.09 mol) and prenyl bromide (1-bromo-3-methyl-2-butene) (16.0 g, 0.11 mol). The *title compound* (7c) (7.0 g, 50%) was obtained as a colourless oil after vacuum distillation, bp 131–134°C (1.8 mmHg); $\delta_{\rm H}$ (50 MHz,

CDCl₃) 7.40 and 5.82 (2H, 2 br s, amide N H_2), 5.13 (1H, t, allyl γ CH), 2.56 and 2.21 (2H, 2 dd, allyl β C H_2), 1.83 and 1.74 (6H, 2 s, ϵ C H_3), 1.44 (2H, br s, amine N H_2), 1.34 (3H, s, β C H_3); δ C (50 MHz, CDCl₃) 179.49 (s, CO), 135.15 (s, δ C), 117.71 (d, γ CH), 56.74 (s, α C), 38.42 (t, β C H_2), 26.16 and 25.01 (2 q, 2 ϵ C H_3), 17.00 (q, β C H_3); HRMS (FAB): MH $^+$, found 157.1328. C₈H₁₇N₂O requires 157.1341.

4.1.4. C^{α} -Methyl-D,L-cinnamylglycinamide (7d). This compound was prepared as described for H-D,L-Mag-NH2 (7a), 46 except for the toluene extraction that was omitted, and the final extraction performed with neat CHCl₃ (2×250 mL). Starting from N-benzylidene-D,L-alaninamide (4) (27.6 g, 0.16 mol) and cinnamyl bromide (24 mL, 0.16 mol), the title compound (22.7 g, 71%) was obtained as a white crystalline solid after crystallization from EtOAc/ pentane, mp 112-114°C; δ_H (200 MHz, CDCl3) 7.49 and 5.78 (2H, 2 s, amide N H_2), 7.35 (m, 5H, phenyl CH), 6.52 (1H, dd, allyl δCH), 6.17 (1H, m, allyl γCH), 2.94 and 2.30 $(2H, 2 dd, allyl \beta CH_2), 1.51 (2H, s, amine NH_2), 1.43 (3H, s, ami$ βCH_3); δ_C (50 MHz, CDCl₃) 177.87 (s, CO), 135.07 (s, phenyl C), 132.54 (d, γCH), 126.64, 125.54 and 124.30 (3d, phenyl CH), 122.98 (d, δ CH), 55.67 (s, α C), 43.07 (t, βCH_2), 25.68 (q, βCH_3); HRMS (FAB): MH⁺, found 205.1330. C₁₂H₁₇N₂O requires 205.1341.

4.2. General procedure for the enzymatic resolution of 7a-d with *Mycobacterium neoaurum*

To a solution of racemic α -amino amides (7a-d) (100 g) in water (1 L), adjusted to pH 8.0-8.5 with acetic acid, the freeze-dried *M. neoaurum* ATCC 25795^{48,66} (8-10 g) was added. The mixture was shaken (150 rpm) at 40°C until a 40-50% conversion was reached (15-24 h, depending on the substrate) as determined by ammonia development or HPLC analysis. After removing the cell mass by centrifugation, the reaction mixture was filtered over Hyflo, concentrated under reduced pressure (to remove NH₃) and, finally, diluted to 500 mL with water. The L-amino acids (L-2a-c) were separated from the D-amino amides (D-7a-c) by ionexchange column chromatography (Amberlyst A26, strongly basic ion-exchange resin). The D-amino amides were eluted first and recovered by evaporating the aqueous solution. The L-amino acids were obtained by eluting the ion-exchange column with a 2N acetic acid solution and evaporating the eluent to dryness. The L-amino acid L-2d was separated from its D-amino amide (D-7d) by extracting with CHCl₃ (5×100 mL) the aqueous solution which was basified to pH 9 with 5N NaOH. The D-amino amide precipitated from the organic phase on concentrating and cooling, while the L-amino acid crystallized from the aqueous layer after neutralization to pH 7 with 5N HCl and concentration under reduced pressure.

4.2.1. Resolution of C $^{\alpha}$ -methyl-D,L-(γ -methyl)allylgly-cinamide (7b). The enzymatic resolution of C $^{\alpha}$ -methyl-D,L-(γ -methyl)allylglycinamide (32 g, 0.22 mol) was stopped after 46% conversion.

 C^{α} -Methyl-L-(γ -methyl)allylglycine (L-**2b**) (15.0 g, 46%, e.e. 98%) was obtained as a pale yellow solid; $\delta_{\rm H}$ (200 MHz, D₂O+DCl) 4.06 and 3.90 (2H, 2 br s, allyl δ CH₂), 1.77 and 1.58 (2H, 2 d, allyl β CH₂), 0.71 (3H, s,

allyl δCH_3), 0.62 (3H, s, allyl βCH_3); δ_C (50 MHz, D₂O+DCl) 173.36 (s, CO), 137.96 (s, γC), 118.16 (t, δCH_2), 58.89 (s, αC), 44.18 (t, βCH_2), 23.33 and 22.21 (2 q, δCH_3 and βCH_3); HRMS (FAB): MH⁺, found 144.1003. $C_8H_{16}NO_2$ requires 144.1025.

 C^{α} -Methyl-D-(γ -methyl)allylglycinamide (D-7b) (20 g, content 86 wt%, e.e. 85%) was recovered as a pale yellow oil.

4.2.2. Resolution of C $^{\alpha}$ -methyl-D,L-prenylglycinamide (7c). The enzymatic resolution of C $^{\alpha}$ -methyl-D,L-prenylglycinamide (61 g, 0.39 mol) was stopped after 45% conversion

 C^{α} -Methyl-L-prenylglycine (L-2c) (21 g, 34%, e.e. 98%) was recovered as a pale yellow solid; $\delta_{\rm H}$ (200 MHz, D₂O+DCl) 4.77 (br s, allyl γCH and solvent signal), 2.31 (2H, 2dd, allyl βCH₂), 1.41 (3H, s, allyl ε-CH₃), 1.34 (3H, s, allyl ε-CH₃), 1.27 (3H, s, βCH₃); $\delta_{\rm C}$ (50 MHz, D₂O+DCl) 174.00 (s, CO), 140.91 (s, δC), 114.41 (d, γCH), 60.61 (s, αC), 35.53 (t, βCH₂), 25.47 (q, βCH₃), 21.45 and 17.58 (2 q, 2 εCH₃); HRMS (FAB): MH⁺, found 158.1186. $C_8H_{16}NO_2$ requires 158.1181.

 C^{α} -Methyl-D-prenylglycinamide (D-7c) [47 g, approximately 50% (still containing some water), e.e. 80%] was obtained as a pale yellow oil.

4.2.3. Resolution of C^{\alpha}-methyl-D,L-cinnamylglycinamide (7d). Due to the poor solubility of C^{α} -methyl-D,L-cinnamylglycinamide (15 g, 0.074 mol), the enzymatic resolution was performed on a 5% (w/w) suspension. The reaction was stopped after 51% conversion.

 C^{α} -Methyl-L-cinnamylglycine (L-2d) (7.04 g, 47%, e.e. 95%) was obtained as a white solid; $\delta_{\rm H}$ (200 MHz, D₂O) 7.39 (5H, m, phenyl CH), 6.55 (1H, d, allyl δ CH), 6.21 (1H, m, allyl γ -CH), 2.65 and 2.40 (2H, 2 dd, allyl β CH₂), 1.36 (3H, s, β CH₃); $\delta_{\rm C}$ (50 MHz, D₂O+DCl) 173.65 (s, CO), 136.57 (d, γ CH), 136.50 (s, phenyl C), 129.08, 128.41 and 126.66 (3d, phenyl CH), 120.85 (d, δ CH), 60.18 (s, α C), 40.20 (t, β CH₂), 21.43 (q, β CH₃); HRMS (FAB): MH⁺, found 206.1176. C_{12} H₁₆NO₂ requires 206.1181.

 C^{α} -Methyl-D-cinnamylglycinamide (D-7**d**). (6.98 g, 46%, e.e. \geq 98%) was obtained as a pale yellow solid.

4.3. General procedure for the enzymatic resolution of 7a-d with *Ochrobactrum anthropi*

To a solution of racemic α -amino amides (7a-d) (10 g) and MnSO₄·H₂O (15 mg) in H₂O (100 mL), adjusted to pH 6.0–8.0 with acetic acid or H₂SO₄, a crude cell suspension (10 wt%) of *O. anthropi* NCIMB 40321⁶⁷ (1 g) was added. The mixture was shaken (150 rpm) at 50°C until a conversion of 40–50% was reached (ammonia determination). The work-up of the enzymatic resolutions was performed as described above for the enzymatic resolutions with *M. neoaurum*.

4.3.1. Resolution of C $^{\alpha}$ -methyl-D,L-(γ -methyl)allylgly-cinamide (7b). After a conversion of 46% was reached,

chiral HPLC analysis revealed 85% and 72% e.e. values for C^{α} -methyl-L-(γ -methyl)allylglycine (L-**2b**) and C^{α} -methyl-D-(γ -methyl)allylglycinamide (D-**7b**), respectively. Further work-up of the reaction was omitted.

4.3.2. Resolution of \mathbf{C}^{α} **-methyl-D,L-prenylglycinamide** (7c). After a conversion of 62% was reached, chiral HPLC analysis revealed 61% and 98% e.e. values for \mathbf{C}^{α} -methyl-L-prenylglycine (L-**2c**) and \mathbf{C}^{α} -methyl-D-prenylglycinamide (D-**7c**), respectively. Further work-up of the reaction was omitted.

4.3.3. Resolution of C $^{\alpha}$ -methyl-p,L-cinnamylglycinamide (7d). After a conversion of 31% was reached, the work-up of the reaction yielded C $^{\alpha}$ -methyl-L-cinnamylglycine (L-2d) (e.e. 96%) and C $^{\alpha}$ -methyl-p-cinnamylglycinamide (p-7b) (e.e. \geq 98%) as white solids. Further work-up of the reaction was omitted. The e.e. of L-2d improves by re-crystallization from an *i*PrOH/H₂O mixture.

4.3.4. N-tert-Butyloxycarbonyl-L-allylglycine, Boc-L-Agl-**OH** (11).^{74,75} H-L-Agl-OH (0.50 g, 4.34 mmol) and NaOH (0.21 g, 5.21 mmol) in 30 mL of a 1:1 mixture of dioxane/ H₂O was cooled to 0°C. Di-tert-butyl-dicarbonate (Boc₂O) (1.14 g, 5.21 mmol) was added in three portions and the reaction was stirred at room temperature for 24 h. Then, dioxane was evaporated under reduced pressure. Excess of Boc₂O was extracted with diethyl ether and the aqueous layer was acidified to pH 3 with 10% KHSO₄. The aqueous solution was extracted with EtOAc. The organic solution was washed with 10% KHSO₄ and H₂O, dried over anhydrous Na₂SO₄, and evaporated to dryness to give the title compound (0.90 g, 96%) as a colourless oil; $R_{\rm f}$ I 0.35, $R_{\rm f}$ II 0.95, $R_{\rm f}$ III 0.15; $[\alpha]_{\rm D}^{20}$ =+9.5 (c 0.5, MeOH); $\nu_{\rm max}$ (KBr) 3363, 1715, 1698 cm⁻¹; $\delta_{\rm H}$ (250 MHz, CDCl₃) 5.71 (1H, m, γ CH), 5.21 (2H, m, δ CH₂), 5.14 (1H, d, J=8.3 Hz, NH), 4.39 (1H, m, α CH), 2.58 (2H, m, β CH₂), 1.45 (9H, s, Boc CH_3); HRMS (FAB): MH^+ , found 215.2496. $C_{10}H_{17}NO_4$ requires 215.2493.

4.3.5. *N-tert*-Butyloxycarbonyl- C^{α} -methyl-L-allylglycine benzylamide, Boc-L-Mag-NHBzl (12). To a solution of Boc-L-Mag-OH⁶² (900 mg, 3.9 mmol) in CH₂Cl₂ (10 mL) cooled to 0°C, EDC·HCl (752 mg, 3.9 mmol) was added. After 20 min, benzylamine (4.5 mL, 39 mmol) was added and the reaction was stirred at room temperature for 2 days. Then, the solvent was removed and the residue dissolved in EtOAc. The solution was washed with 10% KHSO₄, H₂O, 5% NaHCO₃ and H₂O, dried over anhydrous Na₂SO₄, and evaporated to dryness. The title compound (559 mg, 48%) was crystallized as a white solid from EtOAc/petroleum ether, mp 79–80°C; $R_{\rm f}$ I 0.95, $R_{\rm f}$ II 0.95, $R_{\rm f}$ III 0.55; $[\alpha]_{\rm D}^{20}$ =-15.3 (c 0.5, MeOH); $\nu_{\rm max}$ (KBr) 3332, 1732, 1682, 1650, 1540 cm⁻¹; $\delta_{\rm H}$ (250 MHz, CDCl₃) 7.30 (5H, m, Bzl CH), 6.73 (1H, br s, NHBzl), 5.74 (1H, m, Mag γ CH), 5.16 (2H, m, Mag δ CH₂), 4.88 (1H, s, Mag NH), 4.45 (2H, d, J=5.5 Hz, Bzl C H_2), 2.73 (1H, dd, J=7.3, 14.1 Hz, Mag β C H_2), 2.55 (1H, dd, J=7.6, 14.1 Hz, Mag βCH_2), 1.51 (3H, s, Mag βCH_3), 1.40 (9H, s, Boc CH_3); HRMS (FAB): MH⁺, found 319.2023. C₁₈H₃₅N₃O₆ requires 319.2022.

4.3.6. *N-tert*-Butyloxycarbonyl- α -aminoisobutyryl- C^{α} -

methyl-L-allylglycine benzylamide, Boc-Aib-L-Mag-NHBzl (13). To a solution of Boc-Aib-OH⁸⁶ (565 mg, 2.78 mmol) in CH₂Cl₂ (10 mL) cooled to 0°C, EDC·HCl (533 mg, 2.78 mmol) and HOAt (379 mg, 2.78 mmol) were added. After 30 min CF₃CO₂ H₂-L-Mag-NHBzl [obtained by treatment of the corresponding Boc-protected amino acid benzylamide (12) (590 mg, 1.85 mmol) with a 30% solution of TFA in CH₂Cl₂ for 30 min], neutralized with NMM (1.23 mL, 11.13 mmol), was added. The reaction mixture was stirred for 2 days. Then, EtOAc was added and the solution was extracted with 10% KHSO₄, H₂O, 5% NaHCO₃, H₂O, dried over anhydrous Na₂SO₄, and evaporated to dryness. The title compound (373 mg, 50%) was crystallized as a white solid from EtOAc/petroleum ether, mp 178–179°C; $R_{\rm f}$ I 0.85, $R_{\rm f}$ II 0.95, $R_{\rm f}$ III 0.35; $[\alpha]_{\rm D}^{20}$ = -19.9 (*c* 0.5, MeOH); $\nu_{\rm max}$ (KBr) 3411, 3319, 3294, 1693, 1677, 1646, 1547 cm⁻¹; $\delta_{\rm H}$ (250 MHz, CDCl₃) 7.76 (1H, br s, NHBzl), 7.30 (5H, m, Bzl CH), 6.47 (1H, s, Mag NH), 5.66 (1H, m, Mag γ CH), 5.15 (2H, m, Mag δ CH₂), 4.61 (1H, s, Aib NH), 4.52 (1H, dd, J=7.5, 18.2 Hz, Bzl CH_2), 4.38 (1H, dd, J=7.0, 18.2 Hz, Bzl CH_2), 2.86 (1H, dd, $J=8.3, 16.2 \text{ Hz}, \text{Mag }\beta\text{C}H_2$, 2.42 (1H, dd, J=10.6, 16.2 Hz, Mag βCH_2), 1.59 (3H, s, Aib βCH_3), 1.57 (3H, s, Aib βCH_3), 1.41 (3H, s, Mag βCH_3), 1.27 (9H, s, Boc CH_3); HRMS (FAB): MH⁺, found 404.2555. C₂₂H₃₃N₃O₄ requires 404.2549.

4.3.7. *N-tert*-Butyloxycarbonyl-L-prolyl-α-aminoisobutyryl-C^α-methyl-L-allylglycine benzylamide, Boc-L-Pro-Aib-L-Mag-NHBzl (14). To a solution of Boc-Pro-OH (267 mg, 1.24 mmol) in CH_2Cl_2 (5 mL) cooled to 0°C, EDC·HCl (237 mg, 1.24 mmol) and HOAt (168 mg, 1.24 mmol) were added. After 30 min CF₃CO₂[⊕] ⊕H₂-Aib-L-Mag-NHBzl [obtained by treatment of the corresponding Boc-protected dipeptide benzylamide (13) (250 mg, 0.619 mmol) with a 30% solution of TFA in CH₂Cl₂ for 1 h], neutralized with NMM (409 μL, 3.71 mmol), was added. The reaction mixture was stirred for 2 days. Then, EtOAc was added and the solution was extracted with 10% KHSO₄, H₂O₅, 5% NaHCO₃, H₂O₅, dried over anhydrous Na₂SO₄, and evaporated to dryness. The title compound (294 mg, 95%) was crystallized as a white solid from EtOAc/petroleum ether; mp 58–62°C; $R_{\rm f}$ I 0.80, $R_{\rm f}$ II 0.90, $R_{\rm f}$ III 0.30; $[\alpha]_{\rm D}^{20}$ =-57.9 (c 0.5, MeOH); $\nu_{\rm max}$ (KBr) 3307, 1672, 1541 cm⁻¹; $\delta_{\rm H}$ (250 MHz, CDCl₃) 7.73 (1H, br s, NHBzl), 7.31 (5H, m, Bzl CH), 7.09 (1H, s, NH), 6.50 (1H, s, NH), 5.67 (1H, m, Mag γCH), 5.13 (2H, m, Mag δCH_2), 4.46 (2H, m, Bzl CH_2), 4.09 (1H, m, Pro αCH), 3.36 (2H, m, Pro δ C H_2), 2.94 (1H, dd, J=8.1, 17.6 Hz, Mag βCH_2), 2.46 (1H, dd, J=11.0, 17.6 Hz, Mag βCH_2), 2.06– 1.84 (4H, m, Pro βCH_2 and γCH_2), 1.61 (3H, s, βCH_3), 1.54 $(3H, s, \beta CH_3)$, 1.44 $(9H, s, Boc CH_3)$, 1.43 $(3H, s, \beta CH_3)$; HRMS (FAB): MH^+ , found 501.3060. $C_{27}H_{40}N_4O_5$ requires 501.3077.

4.3.8. *N-tert*-Butyloxycarbonyl-L-allylglycyl-L-prolyl-α-aminoisobutyryl- \mathbb{C}^{α} -methyl-L-allylglycine benzylamide, Boc-L-Agl-L-Pro-Aib-L-MagNHBzl (9). To a solution of Boc-L-Agl-OH (11) (223 mg, 1.04 mmol) in CH₂Cl₂ (5 mL) cooled to 0°C, EDC·HCl (199 mg, 1.04 mmol) and HOAt (141 mg, 1.04 mmol) were added. After 30 min CF₃CO₂ $^{\ominus}$ $^{\oplus}$ H₂-L-Pro-Aib-L-Mag-NHBzl [obtained by treatment of the corresponding Boc-protected tripeptide

benzylamide (14) (260 mg, 0.519 mmol) with a 30% solution of TFA in CH₂Cl₂ for 1 h], neutralized with NMM (343 µL, 3.11 mmol), was added. The reaction mixture was stirred for 2 days. Then, EtOAc was added and the solution was extracted with 10% KHSO₄, H₂O₅, 5% NaHCO₃, H₂O, dried over anhydrous Na₂SO₄, and evaporated to dryness. The title compound (239 mg, 77%) was crystallized as a white solid from EtOAc/petroleum ether, mp 87–88°C; R_f I 0.75, R_f II 0.90, R_f III 0.30; $[\alpha]_D^{20} = -63.2$ (c 0.5, MeOH); ν_{max} (KBr) 3310, 1710, 1674, 1640, 1539 cm⁻¹; $\delta_{\rm H}$ (400 MHz, CDCl₃) 7.63 (1H, br t, J= 5.6 Hz, NHBzl), 7.31 (5H, m, Bzl CH), 6.90 (1H, s, Aib NH), 6.54 (1H, s, Mag NH), 5.71 (1H, m, Agl γCH), 5.66 (1H, m, Mag γ CH), 5.12 (4H, m, Agl and Mag δ CH₂), 5.05 (1H, d, J=8.8 Hz, Agl NH), 4.55 (1H, dd, J=6.5, 14.9 Hz, Bzl C H_2), 4.42 (1H, m, Agl α CH), 4.31 (1H, dd, J=5.3, 14.9 Hz, Bzl CH_2), 4.28 (1H, m, Pro αCH), 3.67 and 3.47 $(2H, 2m, Pro \delta CH_2), 3.01 (1H, dd, J=6.8, 14.0 Hz, Mag)$ βCH_2), 2.48 (1H, dd, J=8.2, 14.0 Hz, Mag βCH_2), 2.30 (2H, m, Agl β C H_2), 1.91 (4H, m, Pro β C H_2 and γ C H_2), 1.53 (3H, s, Mag βCH_3), 1.44 (3H, s, Aib βCH_3), 1.43 (9H, s, Boc CH_3), 1.40 (3H, s, Aib βCH_3); HRMS (FAB): MH^+ , found 598.3598. $C_{32}H_{47}N_5O_6$ requires 598.3605.

4.3.9. Cyclic peptide 17. Boc-L-Agl-L-Pro-Aib-L-Mag-NHBzl (9) (80 mg, 0.13 mmol) and Grubbs' catalyst 15 (5.7 mg, 6.7 µmol) were combined in dry and deoxygenated toluene (8 mL). After stirring for 16 h at 80°C under N₂, the solution was concentrated and purified by flash chromatography (EtOAc) to give the cyclic peptide 16 (63 mg, 82%) as a pale yellow oil (mixture of two C=C bond Part diastereomers). of this compound (14 mg,0.024 mmol) and PtO₂ (cat.) were dissolved in EtOAc (2 mL) under an H₂-atmosphere. After stirring for 20 h at room temperature, the solution was filtrated through celite, concentrated, and purified by flash chromatography (EtOAc) to give the *title compound* (12 mg, 85%) as a waxy solid; $R_{\rm f} {\rm IV}~0.25;~\nu_{\rm max}~({\rm film})~3295,~1679,~1642~{\rm cm}^ \delta_{\rm H}$ (400 MHz, CDCl₃) 7.25 (6H, m, Bzl NH and aromatic CH), 6.93 (1H, s, Mag NH), 6.64 (1H, s, Aib NH), 5.19 (1H, d, J=8.4 Hz, Agl NH), 4.42 (3H, m, Bzl CH₂ and Agl α CH), 4.23 (1H, m, Pro α CH), 3.83 and 3.65 (2H, 2m, Pro δ CH₂), 2.35-2.20 (2H, m, Pro βCH₂), 2.05-1.90 (4H, m, Agl 1 βCH_2 , Mag 1 βCH_2 and Pro γCH_2), 1.75–1.25 (13H, m, Agl 1 βCH_2 , Mag 1 βCH_2 , Agl γCH_2 and Aib and Mag βCH_3), 1.44 (9H, s, Boc CH_3), 0.88 (2H, m, Agl δCH_2); HRMS (FAB): MH⁺, found 572.3433. C₃₀H₄₆N₅O₆ requires 572.3448.

4.4. Mass spectrometry

Fast Atom Bombardment (FAB) mass spectrometry was carried out using a JEOL SX/SX model 102A four-sector tandem mass spectrometer ($B_1E_1B_2E_2$ geometry), coupled to a JEOL MS/MP9021D/UPD data system. The samples were loaded in a nitrobenzyl alcohol solution onto a stainless steel probe and bombarded with xenon atoms with an energy of 8 KeV. During the high-resolution FABMS measurements a resolving power of 5000–10,000 (10% valley definition) was used. Polyethyleneglycol (PEG) 300 and 600 was used to calibrate the mass spectrometer.

4.5. Nuclear magnetic resonance

The 1H NMR spectra were recorded by means of Bruker model AC 200, AC250 or AM 400 spectrometers. Deuterated chloroform (99.96% D) and water (99.98% D) were purchased from Aldrich, while deuterated DMSO (99.96% D_6) was obtained from Acros Organics. The free-radical TEMPO was a Sigma product.

References

- Van Meerssche, M.; Declercq, J. P.; Germain, G.; Bouché, R.; Draguet-Brughmans, M. Bull. Soc. Chim. Belg. 1982, 91, 199–204.
- Stilz, H. U.; Jablonka, B.; Just, M.; Knolle, J.; Paulus, E. F.;
 Zoller, G. J. Med. Chem. 1996, 39, 2118–2122.
- Hanessian, S.; Lu, P. P.; Sancéau, J.-Y.; Chemla, Ph.; Gohda, K.; Fonne-Pfister, R.; Prade, L.; Cowan-Jakob, S. W. Angew. Chem. Int., Ed. Engl. 1999, 38, 3160–3162.
- Oka, M.; Matsumoto, Y.; Sugiyama, S.; Tsuruta, N.; Matsushima, M. J. Med. Chem. 2000, 43, 2479–2483.
- Marshall, G. In *Intra-Science Chemistry Reports*, Kharasch, N., Ed.; Gordon and Breach: New York, 1971; pp 305–316.
- Spatola, A. F. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Dekker: New York, 1983; Vol. 7, pp 267–357.
- Aubry, A.; Boussard, G.; Cung, M. T.; Marraud, M.; Vitoux, B. J. Chim. Phys. 1988, 85, 345–359.
- Hruby, V. J.; Al-Obeidi, F.; Kazmierski, W. Biochem. J. 1990, 268, 249–262.
- 9. Karle, I. L.; Balaram, P. Biochemistry 1990, 29, 6747-6756.
- Toniolo, C.; Benedetti, E. *Macromolecules* 1991, 24, 4004–4009.
- Toniolo, C.; Crisma, M.; Formaggio, F.; Valle, G.; Cavicchioni, G.; Précigoux, G.; Aubry, A.; Kamphuis, J. *Biopolymers* 1993, 33, 1061–1072.
- Jaun, B.; Tanaka, M.; Seiler, P.; Kühnle, F. N. M.; Braun, C.;
 Seebach, D. *Liebigs Ann. Chem.* 1997, 1697–1710.
- 13. Imawaka, N.; Tanaka, M.; Suemune, H. *Helv. Chim. Acta* **2000**, *83*, 2823–2835.
- 14. Venkatachalam, C. M. Biopolymers 1968, 6, 1425–1436.
- 15. Toniolo, C. C.R.C. Crit. Rev. Biochem. 1980, 9, 1-44.
- Rose, G. D.; Gierasch, L. M.; Smith, J. P. Adv. Protein Chem. 1985, 37, 1–109.
- Toniolo, C.; Benedetti, E. Trends Biochem. Sci. 1991, 16, 350–353.
- Cung, M. T.; Marraud, M.; Néel, J. Ann. Chim. (Paris) 1972, 7, 183–209.
- Toniolo, C.; Benedetti, E. In Molecular Conformation and Biological Interactions, Balaram, P., Ramaseshan, S., Eds.; Indian Academy of Sciences: Bangalore, India, 1991; pp 511–521.
- 20. Voyer, N.; Lamothe, J. Tetrahedron 1995, 51, 9241-9284.
- 21. Kaul, R.; Balaram, P. Bioorg. Med. Chem. 1999, 7, 105-117.
- Andrews, M. J. I.; Tabor, A. B. Tetrahedron 1999, 55, 11711– 11743.
- 23. Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413-4450.
- Armstrong, S. K. J. Chem. Soc., Perkin Trans. 1 1998, 371– 388.
- Broxterman, Q. B.; Kaptein, B.; Kamphuis, J.; Schoemaker, H. E. J. Org. Chem. 1992, 57, 6286–6294.

- Collier, Ph.; Campbell, A. D.; Patel, I.; Taylor, R. J. K. Tetrahedron Lett. 2000, 41, 7115–7119.
- Hanessian, S.; Yang, R. Y.; Sancéau, J. Y. Can. J. Chem. 1997, 75, 712–715.
- Receveur, J. M.; Guiramand, J.; Récasens, M.; Roumestant, M. L.; Viallefont, Ph.; Martinez, J. *Bioorg. Med. Chem. Lett.* 1998, 8, 127–132.
- 29. Hoarau, S.; Fauchère, J. L.; Pappalardo, L.; Roumestant, M. L.; Viallefont, Ph. *Tetrahedron: Asymmetry* **1996**, *7*, 2585–2593.
- 30. Denniel, V.; Bauchat, P.; Danion, D.; Danion-Bougot, R. *Tetrahedron Lett.* **1996**, *37*, 5111–5114.
- Easton, C. J.; Merret, M. C. Tetrahedron 1997, 53, 1151– 1156.
- Girard, A.; Greck, C.; Genêt, J. P. Tetrahedron Lett. 1998, 39, 4259–4260.
- 33. Zaragoza, F. Tetrahedron 1997, 53, 3425-3439.
- Poché, D. S.; Thibodeaux, S. J.; Rucker, V. C.; Warner, I. M.;
 Daly, W. H. *Macromolecules* 1997, 30, 8081–8084.
- Semple, J. E.; Minami, N. K.; Tamura, S. Y.; Brunck, T. K.;
 Nutt, R. F.; Ripka, W. C. *Bioorg. Med. Chem. Lett.* 1997, 7, 2421–2426.
- Miller, S. J.; Blackwell, H. E.; Grubbs, R. H. J. Am. Chem. Soc. 1996, 118, 9606–9614.
- Jarvo, E. R.; Copeland, G. T.; Papaioannou, N.; Bonitatebus Jr., P. J.; Miller, S. J. J. Am. Chem. Soc. 1999, 121, 11638– 11643
- Blackwell, H. E.; Grubbs, R. H. Angew. Chem., Int. Ed. Engl. 1998, 37, 3281–3284.
- 39. Williams, R. M.; Liu, J. J. Org. Chem. 1998, 63, 2130-2132.
- 40. Fujii, N.; Hirohashi, M.; Oishi, S.; Akaji, M.; Omagari, A.; Otaka, A.; Ibuko, T. In *Peptide Science 1999*, Fujii, N., Ed.; The Japanese Peptide Society: Tokyo, 2000; pp 193–194.
- 41. Ripka, A. S.; Bohacek, R. S.; Rich, D. A. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 357–360.
- 42. Fink, B. E.; Kym, Ph. R.; Katzenellenbogen, J. A. J. Am. Chem. Soc. 1998, 120, 4334–4344.
- 43. Pernerstorfer, J.; Schuster, M.; Blechert, S. *J. Chem. Soc.*, *Chem. Commun.* **1997**, 1949–1950.
- Schafmeister, C. E.; Po, J.; Verdine, G. L. J. Am. Chem. Soc. 2000, 122, 5891–5892.
- 45. van der Werf, A.; Kellogg, R. M. *Tetrahedron Lett.* **1988**, *29*, 4981–4984.
- Kaptein, B.; Boesten, W. H. J.; Broxterman, Q. B.; Schoemaker, H. E.; Kamphuis, J. *Tetrahedron Lett.* 1992, 33, 6007–6010.
- Schoemaker, H. E.; Boesten, W. H. J.; Kaptein, B.; Hermes,
 H. F. M.; Sonke, T.; Broxterman, Q. B.; van den Tweel,
 W. J. J.; Kamphuis, J. Pure Appl. Chem. 1992, 64, 1171–1175.
- 48. Kaptein, B.; Boesten, W. H. J.; Broxterman, Q. B.; Peters, P. J. H.; Schoemaker, H. E.; Kamphuis, J. *Tetrahedron: Asymmetry* **1993**, *4*, 1113–1116.
- Veerman, J. J. N.; van Maarseveen, J. H.; Visser, G. M.; Kruse, C. G.; Schoemaker, H. E.; Hiemstra, H.; Rutjes, F. P. J. T. Eur. J. Org. Chem. 1998, 2583–2589.
- Rutjes, F. P. J. T.; Veerman, J. J. N.; Meester, W. J. N.; Hiemstra, H.; Schoemaker, H. E. Eur. J. Org. Chem. 1999, 1127–1135.
- 51. Phillips, A. J.; Abell, A. D. Aldrichim. Acta 1999, 32, 75–90.
- Rutjes, F. P. J. T.; Schoemaker, H. E. Tetrahedron Lett. 1997, 38, 677–680.
- Berkowitz, D. B.; Pedersen, M. L.; Jahng, W. J. *Tetrahedron Lett.* 1996, 37, 4309–4312.

- Badorrey, R.; Cativiela, C.; Diaz-de-Villegas, M. D.; Galvez,
 J. A.; Lapeña, Y. *Tetrahedron: Asymmetry* 1997, 8, 311–317.
- Loreto, M. A.; Pompei, F.; Tardella, P. A.; Tofani, D. Tetrahedron 1997, 53, 15853–15858.
- Chinchilla, R.; Galindo, N.; Najera, C. Synthesis 1999, 4, 704–717.
- Trost, B. M.; Ariza, X. J. Am. Chem. Soc. 1999, 121, 10727– 10737.
- 58. Ojima, I.; Delaloge, F. Chem. Soc. Rev. 1997, 26, 377-386.
- Williams, R. M. In *Methods in Molecular Medicine: Peptido-mimetics Protocols*; Kazmierski, W. M., Ed.; Humana: Totowa, NJ, 1999; Vol. 23, pp 339–356.
- Genêt, J. P.; Juge, S.; Besnier, I.; Uziel, J.; Ferroud, D.; Kardos, N.; Achi, S.; Ruiz-Montes, J.; Thorimbert, S. *Bull. Soc. Chim. Fr.* 1990, 127, 781–786.
- Williams, R. M.; Im, M. N. J. Am. Chem. Soc. 1991, 113, 9276–9286.
- 62. Peggion, C.; Flammengo, R.; Mossel, E.; Broxterman, Q. B.; Kaptein, B.; Kamphuis, J.; Formaggio, F.; Crisma, M.; Toniolo, C. *Tetrahedron* **2000**, *56*, 3589–3601.
- Crisma, M.; Peggion, C.; Formaggio, F.; Toniolo, C.; Vitale, R. M.; Iacovino, R.; Saviano, M.; Benedetti, E.; Broxterman, Q. B.; Kaptein, B.; Kamphuis, J. In *Peptides 2000*, Martinez, J., Fehrentz, J.-A., Eds.; Editions EDK: Paris, 2001; pp 401–410
- 64. Cativiela, C.; Diaz-de-Villegas, M. D. *Tetrahedron: Asymmetry* **2000**, *11*, 645–732.
- Sonke, T.; Kaptein, B.; Boesten, W. H. J.; Broxterman, Q. B.; Kamphuis, J.; Formaggio, F.; Toniolo, C.; Rutjes, F. P. J. T.; Schoemaker, H. E. In *Stereoselective Biocatalysis*, Patel, R. N., Ed.; Dekker: New York, 2000; pp 23–58.
- Kruizinga, W. H.; Bolster, J.; Kellogg, R. M.; Kamphuis, J.;
 Boesten, W. H. J.; Meijer, E. M.; Schoemaker, H. E. *J. Org. Chem.* 1988, 53, 1826–1827.
- van den Tweel, W. J. J.; van Doren, T. J. G. M.; de Jonge,
 P. H.; Kaptein, B.; Duchateau, A. L. L.; Kamphuis, J. Appl. Microbiol. Biotechnol. 1993, 39, 296–300.
- Chen, C. S.; Fujimoto, Y.; Girdaukas, G.; Sih, C. J. J. Am. Chem. Soc. 1982, 104, 7294–7299.
- 69. Moretto, A.; Peggion, C.; Formaggio, F.; Crisma, M.; Toniolo, C.; Piazza, C.; Kaptein, B.; Broxterman, Q. B.; Ruiz, I.; Diazde-Villegas, M. D.; Galvez, J. A.; Cativiela, C. *J. Pept. Res.* **2000**, *56*, 283–297.
- Elferink, V. H. M.; Breitgoff, D.; Kloosterman, M.; Kamphuis, J.; van den Tweel, W. J. J.; Meijer, E. M. Recl. Trav. Chim. Pays-Bas 1991, 110, 63-74.
- 71. Van Betsbrugge, J.; Tourwé, D.; Kaptein, B.; Kierkels, H.; Broxterman, Q. B. *Tetrahedron* **1997**, *53*, 9233–9240.
- Ravi, A.; Venkataram Prasad, B. V.; Balaram, P. J. Am. Chem. Soc. 1983, 105, 105–109.
- Di Blasio, B.; Pavone, V.; Saviano, M.; Lombardi, A.; Nastri,
 F.; Pedone, C.; Benedetti, E.; Crisma, M.; Anzolin, M.;
 Toniolo, C. J. Am. Chem. Soc. 1992, 114, 6273–6278.
- 74. Myers, A. G.; Gleason, J. L. Org. Synth. 1998, 76, 57-76.
- 75. Guillena, G.; Najera, C. J. Org. Chem. 2000, 65, 7310-7312.
- 76. Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397-4398.
- Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem., Int. Ed. Engl. 1995, 34, 2039–2041.
- Scholl, M.; Trnka, T. M.; Morgan, J. P.; Grubbs, R. H. Tetrahedron Lett. 1999, 40, 2247–2250.
- 79. Kopple, K. D.; Ohnishi, M. Biochemistry 1969, 8, 4087–4095.
- 80. Martin, D.; Hauthal, G. *Dimethyl Sulphoxide*, van Nostrand-Reinhold: Wokingham, UK, 1975.

- 81. Kopple, K. D.; Schamper, T. J. J. Am. Chem. Soc. **1972**, 94, 3644–3646.
- 82. Williams, K. A.; Deber, C. M. *Biochemistry* **1991**, *30*, 8919–8923.
- 83. Yaron, A.; Naider, F. C.R.C. Crit. Rev. Biochem. **1993**, 28, 31–81.
- 84. Duchateau, A. L. L.; Knuts, H.; Boesten, J. M. M.; Guns, J. J. *J. Chromatogr.* **1992**, *623*, 237–245.
- 85. Schatz, P. F. J. Chem. Educ. 1978, 55, 468-470.
- 86. Mayr, W.; Oekonomopulos, R.; Jung, G. *Biopolymers* **1979**, *18*, 425–450.